Stroke is the second cause of death worldwide and represented the first cause of death in Brazil between 2006 and 2010. Most patients survive, and there is a need to develop cost-effective rehabilitation strategies to decrease the burden of disability from stroke. This study addresses this important issue, by evaluating, in the early phase post-stroke, effects of motor conventional physical therapy associated or not with transcranial direct current stimulation (tDCS).
The investigators main goal is to confirm the safety of transcranial direct current stimulation (tDCS) associated with conventional physical therapy, compared to conventional physical therapy associated with sham tDCS, for upper limb rehabilitation in an early phase (72 hours until 6 weeks) after stroke. Patients will be randomized to receive one of these two treatments, 3 times per week, for 2 weeks. Adverse effects will be monitored during each session. The working hypothesis is that conventional physical therapy associated with active tDCS in the subacute phase of ischemic stroke will be as safe as conventional therapy alone. The investigators will also preliminarily evaluate the efficacy of active tDCS associated with conventional therapy, compared to conventional therapy alone, in improvement of upper limb motor impairment. The investigators secondary goals are: 1) To compare effects of the above mentioned interventions on disability, spasticity and quality of life, in patients at an early stage after stroke ( subacute phase), immediately after treatment and 3 months later. The investigators hypothesis is that the association of conventional physical therapy and active tDCS will lead to better outcomes than conventional therapy alone. Patients will be assessed before the first session and after the last session of treatment, as well as 3 months after the last session of treatment. Preliminary data about structural and functional connectivity will be collected in order to plan future studies related to mechanisms of tDCS in the subacute phase after stroke.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
30
Active tDCS will be applied with the anode positioned over the ipsilesional primary motor cortex and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
Physical therapy will be administered for 60 minutes
In sham tDCS, no current will be delivered through the tDCS device.
Danielle Boasquevisque
São Paulo, Brazil
Safety of the intervention as assessed by frequency of adverse events
frequency of adverse events in the active and sham arms
Time frame: 2 weeks
Improvement post treatment as measured by the Modified Rankin Scale
Improvement post treatment
Time frame: 2 weeks and 14 weeks
Improvement post treatment as measured by the NIH Stroke Scale
Improvement post treatment
Time frame: 2 weeks and 14 weeks
Improvement post treatment as measured by the Stroke Impact Scale
Improvement post treatment
Time frame: 2 weeks and 14 weeks
Upper limb subscale of Fugl Meyer Assessment of Sensorimotor recovery after stroke
Improvement post treatment
Time frame: 2 weeks and 14 weeks
Improvement post treatment as measured by the Modified Ashworth Scale
Improvement post treatment
Time frame: 2 weeks and 14 weeks
Improvement post treatment as measured by the Motor Activity Log
Improvement post treatment
Time frame: 2 weeks and 14 weeks
Montreal Cognitive Assessment Test
No cognitive deterioration post treatment
Time frame: 2 weeks and 14 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Structural Connectivity as measured by diffusion tensor imaging analysis
Improvement post treatment
Time frame: 2 weeks
Functional Connectivity as measured by resting-state functional magnetic imaging analysis
Improvement post treatment
Time frame: 2 weeks
Improvement post treatment as measured by the Barthel index
Improvement post treatment
Time frame: 2 week and 14 weeks
Safety of the intervention as assessed by frequency of adverse events
frequency of adverse events in the active and sham arms
Time frame: 14 weeks
Improvement post treatment as measured by Pittsburgh Sleep Quality Index
Improvement post treatment
Time frame: 2 week and 14 weeks